DM me if you want a structured plan that includes proper monitoring
Demonstrating biological activity whether administered systemically, locally, orally, or intraperitoneally in pre-clinical models and and by the breadth of its cytoprotective, tissue repair, and angiogenic effects across virtually every organ system examined in the research literature
La forma L-ridotta quella biologicamente attiva
Recognised Side Effects and Safety Profile of Mounjaro Mounjaro has a well-characterised safety profile based on clinical trial data and post-marketing surveillance
Pre-existing gastrointestinal conditions People with irritable bowel syndrome, gastroparesis, gastroesophageal reflux disease, or chronic constipation are significantly more likely to experience early and intense side effects
The CMAJ guidance A guidance article published in the Canadian Medical Association Journal (CMAJ) on glucagon-like peptide-1 receptor agonists during pregnancy and lactation concluded that while the safety data is limited, the pharmacological properties of GLP-1 agonists (large molecular weight, poor oral bioavailability) suggest low theoretical risk during breastfeeding